Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, today announced the U.S. commercial availability of its Dayspring active compression system for the treatment of lymphedema and venous diseases in lower extremities. The company also announced that the CMS issued three new billing codes in accordance with the HCPCS for the Dayspring active compression system. The new codes became effective for provider billing on April 1, 2022.
Dayspring is the first non-pneumatic active dynamic compression treatment cleared by the U.S. Food and Drug Administration(FDA). It is specifically designed for patient mobility and is wearable.Dayspring supports essential body movement and mobility so patients can continue their daily activities during treatment, unlike current pneumatic(air-based) compression pumps that require patients to be stationary and the devices to be plugged into an outlet. The Dayspring treatment for the upper extremity has been commercially available since 2021, and the expansion into lower extremity care – available in both full and lower leg applications allows the company to better support people living with lymphedema and venous diseases.
“Daily essential movement helps promote healthy lymph fluid flow, which is important for managing lymphedema, venous insufficiency and other chronic edemas. We designed Dayspring active compression to help patients remain mobile, get the treatment they need instead of letting it get in the way,” said Andy Doraiswamy, Ph.D., Koya Medical founder and CEO. “We look forward to providing at-home active compression treatment options that allow natural leg movements to help reduce swelling and maintain limb volume for people living with lymphedema and venous insufficiency in their lower extremities.”
“Securing codes from CMS is a significant step for advancing new treatment options for patients living with lymphedema and their caregivers and providers,” said Kelly Petrucci, vice president of Strategic Market Access and Health Economics at Koya Medical. “We appreciate the recognition of the new codes, and this significant milestone is critically important to help ensure patients have access to treatments like Daypring.”
The Dayspring system includes a soft, breathable mesh garment made with the company’s proprietary Flexframe technology, which are highly durable spring-like segments designed to deliver controlled and customizable compression while allowing natural movement. The system also comes with a smart, rechargeable and Bluetooth-enabled controller and a companion app that allows users and their clinicians to customize treatments and review treatment history.
About Lymphedema
An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein rich fluid causes painful swelling in the arm, leg, and/or other regions of the body. For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema is commonly caused by cancer and its treatment due to damage of the lymph system from the tumor itself, radiation treatment or the surgical impairment of lymph nodes.
About Dayspring®
Dayspring is a prescription, non-pneumatic compression system designed to deliver customizable active compression while allowing patients to remain mobile during treatment.
Dayspring is the only non-pneumatic compression therapy supported by published randomized head-to-head comparative evidence demonstrating superior limb volume reduction, disease-specific quality of life, treatment adherence and patient preference versus an advanced pneumatic compression device.
Dayspring is FDA-cleared for the treatment of lymphedema, phlebolymphedema, venous insufficiency and other chronic edema-related conditions affecting the upper and lower extremities.
About Koya Medical
Founded in 2018 and headquartered in Dallas, Koya Medical is a medical technology company developing a portfolio of evidence-based treatments designed to improve clinical outcomes and patient experience in vascular disease.
[1] Dean, S. M., Valenti, E., Hock, K., Leffler, J., Compston,A., & Abraham, W. T. (2020). The clinical characteristics of lowerextremity lymphedema in 440 patients. Journalof Vascular Surgery: Venous and Lymphatic Disorders, 8(5), 851–859. https://doi.org/10.1016/j.jvsv.2019.11.014
